

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 550 0959 ext. 106

**Triplos Discovery Research, a subsidiary of Commonwealth
Biotechnologies, Inc. secures a Discovery Milestone Payment from
Gemin X Biotechnologies Inc.**

RICHMOND, VA, MONTREAL, CANADA and BUDE, ENGLAND (August XX , 2007) Triplos Discovery Research (TDR) Limited, a wholly owned subsidiary within the Commonwealth Biotechnologies, Inc. (CBI) group of companies (NASDAQ Capital Market: CBTE) and a leading provider of drug discovery chemistry services and small molecule products announces today that it has secured a milestone payment from Gemin X Biotechnologies Inc., a biopharmaceutical company specializing in the discovery and development of novel small molecule cancer therapeutics.

The milestone payment arises from an agreement announced January 25, 2006 and is the result of significant progress in the identification of a lead preclinical candidate for a Gemin X program in the study of novel ligands to prevent a telomeric DNA/protein interaction implicated in cancer. Through a combination of provision of TDR's LeadQuest® small molecules, deployment of cutting-edge, proprietary chemoinformatics tools, screening technologies and medicinal chemistry expertise, the companies have now identified a lead compound series with promising disease modifying properties.

Commenting on the achievement, Gordon C. Shore, Gemin X's Interim CEO and CSO, stated, "We appreciate the expertise that TDR's scientists have contributed to advance this promising drug discovery program that complements our existing pipeline of small molecules that target specialized cancer pathways that are key to the growth and progression of cancer. We look forward to continued collaborative efforts with TDR that capitalize on both companies' strong science capabilities."

Paul D'Sylva, CEO of Commonwealth Biotechnologies stated that, "We are very pleased to have secured this milestone payment from Gemin X. It further reinforces our belief that in TDR we have acquired a world-class computational and medicinal chemistry group that supports our clients in discovering novel small molecule therapies for their pipelines. We are pleased to continue to work together with Gemin X's team of chemists and biologists as this program continues to advance."

About Gemin X Biotechnologies

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 pro-survival proteins and is

currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers currently in Phase 1 clinical trials. Gemin X is privately held and is located in Montréal, Québec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

About Tripos Discovery Research Limited

Tripos Discovery Research Ltd (“TDR”) is a leading knowledge driven, drug discovery services business that provides pharmaceutical and biotechnology companies with novel approaches to drug discovery. Applying proprietary computational design and therapeutic medicinal chemistry tools and expertise, TDR is able to reduce drug discovery timelines by up to 30%. Since 1997, TDR has been offering compound libraries under the LeadQuest® brand, screening libraries under the LeadScreen® brand and custom de novo compound libraries under the LeadSelect® brand.

About Commonwealth Biotechnologies, Inc

The CBI group offers cutting-edge R&D products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization with a major emphasis in biodefense contracting; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd., Melbourne, Australia, a peptide and discovery chemistry business; and (4) Tripos Discovery Research, Ltd., Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 140 staff in world-class laboratories. For more information, visit CBI on the web at www.cbi-biotech.com

Forward Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding CBI’s expectations, beliefs, intentions or strategies regarding the future. Forward-looking statements include, but are not limited to, express or implied statements regarding future revenues, revenue growth and profitability, and the markets for its services. All forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. These and other risks relating to CBI’s business are set forth in CBI’s Form 10-KSB filed with the Securities and Exchange Commission on March 30, 2007, and CBI’s Form 10-QSBs and other reports filed from time to time with the Securities and Exchange Commission.